Zinc (Zn) has the potential of regulating the action of thiazolidinedione (TZD), an anti-diabetic drug. Since some diabetic patients cannot achieve optimal glycemic control when receiving TZD, we investigated if Zn deficiency affects TZD’s efficacy in glucose metabolism. Diabetic mice were fed diets containing 3 or 30 mg/kg Zn for 6 weeks. Thereafter, all mice were oral gavaged with 2,4-thiazolidinedione. Our results showed that blood glucose values at fasting and during the glucose tolerance test were significantly higher in low-Zn mice than those of adequate-Zn mice. Thus, low Zn intake may attenuate TZD’s efficacy on reducing diabetic hyperglycemia.
Andrikopoulos S , Blair AR, Deluca N, Fam BC, Proietto J: Evaluating the glucose tolerance test in mice. Am. J. Physiol. Endocrinol. Metab. 295, E1323–E1332 (2008)
Ceriello A : New insights on oxidative stress and diabetic complications may lead to a “causal” antioxidant therapy. Diabetes Care 26, 1589–1596 (2003)
Chawla A , Nguyen KD, Goh YP: Macrophage-mediated inflammation in metabolic disease. Nat. Rev. Immunol. 11, 738–749 (2011)
Hsu MH , Palmer CN, Song W, Griffin KJ, Johnson EF: A carboxyl-terminal extension of the zinc finger domain contributes to the specificity and polarity of peroxisome proliferator-activated receptor DNA binding. J. Biol. Chem. 273, 27988–27997 (1998)
Hung YJ , Lin SH, Pei D, Kuo SW, Hsieh CH, He CT, Hsing LC, Fan SC, Sheu WH: Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance. Metabolism 55, 439–444 (2006)
Jansen J , Karges W, Rink L: Zinc and diabetes: clinical links and molecular mechanisms. J. Nutr. Biochem. 20, 399–417 (2009)
Maret W : Zinc biochemistry: from a single zinc enzyme to a key element of life. Adv. Nutr. 4, 82–91 (2013)
Meerarani P , Reiterer G, Toborek M, Hennig B: Zinc modulates PPARr signaling and activation of porcine endothelial cells. J. Nutr. 133, 3058–3064 (2003)
Myers SA , Nield A, Myers M: Zinc transporters, mechanisms of action and therapeutic utility: implications for type 2 diabetes mellitus. J. Nutr. Metab. 2012, 173712 (2012)
Prasad AS : Impact of the discovery of human zinc deficiency on health. J. Am. Coll. Nutr. 28, 257–265 (2009)
Reiterer G , Toborek M, Hennig B: Peroxisome proliferator activated receptors a and r require zinc for their antiinflammatory properties in porcine vascular endothelial cells. J. Nutr. 134, 1711–1715 (2004)
Semple RK , Chatterjee VK, O’Rahilly S: PPAR gamma and human metabolic disease. J. Clin. Invest. 116, 581–589 (2006)
Shaw JE , Sicree RA, Zimmet PZ: Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 87, 4–14 (2010)
Shen H , MacDonald R, Bruemmer D, Stromberg A, Daugherty A, Li X, Toborek M, Hennig B: Zinc deficiency alters lipid metabolism in LDL receptor-deficient mice treated with rosiglitazone. J. Nutr. 137, 2339–2345 (2007)
Simon SF , Taylor CG: Dietary zinc supplementation attenuates hyperglycemia in db/db mice. Exp. Biol. Med. 226, 43–51 (2001)
Tontonoz P , Spiegelman BM: Fat and beyond: the diverse biology of PPARgamma. Ann. Rev. Biochem. 77, 289–312 (2008)
Vardatsikos G , Panday NR, Srivastava AK: Insulino-mimetics and anti-diabetic effects of zinc. J. Inorg. Biochem. 120, 8–17 (2013)
Wessells KR , Brown KH: Estimating the global prevalence of zinc deficiency: results based on zinc availability in national food supplies and the prevalence of stunting. PLoS. One. 7, e50568 (2012)